A case of Stevens–Johnson syndrome in a patient on ipilimumab

Mohini Pathria, Jyoti Mundi, Joshua Trufant

ABSTRACT

Introduction: Stevens–Johnson syndrome is a rare complication of ipilimumab therapy. A brief review of literature on the dermatologic adverse effects of ipilimumab is presented. This paper aims to heighten awareness of the significant risk and potential severity of cutaneous adverse effects associated with the use of ipilimumab.

Case Report: A case of 71-year-old woman being treated with ipilimumab for stage IV choroidal melanoma who presented with Stevens–Johnson syndrome 2.5 weeks after her last ipilimumab infusion.

Conclusion: Delayed diagnosis of Stevens–Johnson syndrome in patients receiving ipilimumab therapy can lead to devastating outcomes.
A case of Stevens–Johnson syndrome in a patient on ipilimumab

Mohini Pathria, Jyoti Mundi, Joshua Trufant

ABSTRACT

Introduction: Stevens–Johnson syndrome is a rare complication of ipilimumab therapy. A brief review of literature on the dermatologic adverse effects of ipilimumab is presented. This paper aims to heighten awareness of the significant risk and potential severity of cutaneous adverse effects associated with the use of ipilimumab. Case Report: A case of 71-year-old woman being treated with ipilimumab for stage IV choroidal melanoma who presented with Stevens–Johnson syndrome 2.5 weeks after her last ipilimumab infusion. Conclusion: Delayed diagnosis of Stevens–Johnson syndrome in patients receiving ipilimumab therapy can lead to devastating outcomes.

Keywords: Ipilimumab, Melanoma, Stevens–Johnson syndrome

INTRODUCTION

Ipilimumab is a monoclonal human antibody directed against cytotoxic T lymphocyte antigen-4 (anti-CTLA-4). The medication helps increase T cell activation [1]. The therapy has been recently approved for management of metastatic melanoma. Common adverse effects involve the gastrointestinal tract and skin [2]. Skin reactions can range from mild to severe, including Stevens–Johnson syndrome (SJS) [2]. Stevens–Johnson syndrome is characterized by epidermal death and separation involving less than 10% of the skin surface. If more than 30% of the skin is involved, the syndrome is considered toxic epidermal necrolysis (TEN), with SJS/TEN overlap for involvement of 10–30% of the skin surface [3]. Stevens-Johnson syndrome (SJS) and/or toxic epidermal necrolysis (TEN) with ipilimumab therapy is a rare complication and the exact frequency is unknown. Delayed diagnosis can lead to devastating complications.

CASE REPORT

A 71-year-old female was being treated for stage IV choroidal melanoma with ipilimumab. Two and a half weeks after her third infusion, she presented with a progressively painful rash on her face, trunk, and extremities, ocular discharge, and dysuria. Physical examination revealed conjunctival injection, painful crusted erosions on her vermillion, mucosal lip and labia majora, and dusky targetoid patches on her forehead and extremities. The patient’s trunk was diffusely
erythematous and tender. Nikolsky’s sign was present and spontaneous sloughing was noted over approximately 25% of the patient’s body surface area (Figure 1). The affected epidermis was submitted for frozen sections and a 4-mm punch biopsy was performed (Figure 2A–B). The biopsy demonstrated full-thickness epidermal necrosis with a sparse perivascular lymphocytic infiltrate. The clinical and histologic findings were consistent with Stevens–Johnson syndrome. The patient was transferred to a burn unit. The patient was treated with supportive measures including artificial tears and Lacrilube to the eyes. Daily vitamin A and vitamin D ointment and xeroform was applied to denuded skin. She received intravenous fluid resuscitation and tube feedings to enhance protein intake. She has fully recovered from this episode and has resumed her baseline quality of life.

**DISCUSSION**

Ipilimumab is a monoclonal immunoglobulin G1 antibody directed against cytotoxic T lymphocyte antigen-4 (anti-CTLA-4). The medication received FDA approval in 2011 as monotherapy for metastatic melanoma for four cycles at a dose of 3 mg/kg administered intravenously every three weeks for 90 minutes [1]. CTLA-4 diminishes T cell activation by competing with CD28 on T cells for co-stimulatory molecules on antigen presenting cells [1]. In metastatic melanoma, T cells are functionally impaired, while inhibitory receptors, such as CTLA-4, are upregulated [4]. In vivo studies have demonstrated that CTLA-4 blockade can promote antitumor immunity [5].

Antibody inhibition of CTLA-4 is associated with immune-related adverse events (IRAEs), mainly affecting the skin, gastrointestinal, and endocrine systems. Cutaneous IRAEs occur after 2 to 3 weeks, gastrointestinal IRAEs occur after 6 to 7 weeks, and endocrinologic IRAEs have been described after an average of 9 weeks. A dose-dependent increase in the frequency of IRAEs of any grade has been noted [2].

Dermatologic adverse effects include rash, pruritus, and vitiligo. The incidence of all-grade rash in patients receiving ipilimumab was 24.3%. The overall incidence of high-grade rash was 2.4% [1]. Cutaneous lesions associated with ipilimumab have been described as itchy, erythematous, discrete, mildly scaly papules coalescing into thin plaques on the trunk and proximal aspects of extensor extremities. The head and neck can be involved, while palms and soles are usually spared. Koebnerization may occur. Patients can develop a peripheral eosinophilia. On histology, a perivascular CD4+ T cell infiltrate with eosinophils is seen in the superficial dermis. Epidermal spongiosis and, rarely, dyskeratosis are also observed. Other skin findings include alopecia of the scalp, eyebrows, face, pubic region, and trunk as well as a photosensitive eruption [6]. Additionally, anti-CTLA-4 antibodies may stimulate an immune response against melanocytes. The development of vitiligo in a subset of patients and the identification of Melan-A-specific CD8+ T lymphocytes near apoptotic melanocytes in biopsy specimens supports this theory [2, 6].

Stevens–Johnson syndrome and toxic epidermal necrolysis is a rare yet severe cutaneous adverse effect of ipilimumab. Recommended management of SJS and TEN involves early removal of the causative drug. Supportive therapy is initiated with protective measures for the exposed skin and mucosa, early detection and management of infection, fluid and nutritional support, and pain control [3]. Although initiation of prednisone at 1–2 mg/kg is recommended in patients with high grade IRAEs due to ipilimumab [2], caution is urged as the benefit of systemic corticosteroids in the treatment of SJS-TEN is debated and their use may be detrimental [3].

**CONCLUSION**

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, but potentially fatal occurrences while undergoing ipilimumab therapy. The TEN has a high risk of mortality due to infections and retrospective data supports early referral to a burn unit. Given the increasing use of ipilimumab in patients with
metastatic melanoma, it is important for oncologists and dermatologists to be aware of the significant risk and potential severity of cutaneous adverse effects associated with the medication.

*********

Acknowledgements
We would like to acknowledge Dr. Rishi R. Patel, Assistant Professor at the Ronald O. Perelman Department of Dermatology and the Department of Pathology at NYU Langone Medical Center for his contribution to this case. Dr. Rishi R. Patel provided histological confirmation of the diagnosis. Dr. Rishi R. Patel did not receive any financial compensation for his contribution.

Author Contributions
Mohini Pathria – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Jyoti Mundi – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published

Joshua Trufant – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© 2016 Mohini Pathria et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited.

Please see the copyright policy on the journal website for more information.

REFERENCES


SUGGESTED READING


Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.*

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.*

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

* Terms and condition apply. Please see Edorium Journals website for more information.

We welcome you to interact with us, share with us, join us and of course publish with us.